- Home
- FOUR vs LEGN Comparison
FOUR vs LEGN Comparison
Compare FOUR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOUR
- LEGN
- Stock Information
- Founded
- FOUR 1999
- LEGN 2014
- Country
- FOUR United States
- LEGN United States
- Employees
- FOUR N/A
- LEGN N/A
- Industry
- FOUR Business Services
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- FOUR Consumer Discretionary
- LEGN Health Care
- Exchange
- FOUR Nasdaq
- LEGN Nasdaq
- Market Cap
- FOUR 6.9B
- LEGN 6.3B
- IPO Year
- FOUR 2020
- LEGN 2020
- Fundamental
- Price
- FOUR $73.94
- LEGN $31.98
- Analyst Decision
- FOUR Buy
- LEGN Strong Buy
- Analyst Count
- FOUR 20
- LEGN 12
- Target Price
- FOUR $109.47
- LEGN $70.82
- AVG Volume (30 Days)
- FOUR 2.3M
- LEGN 1.4M
- Earning Date
- FOUR 11-06-2025
- LEGN 11-11-2025
- Dividend Yield
- FOUR N/A
- LEGN N/A
- EPS Growth
- FOUR 55.45
- LEGN N/A
- EPS
- FOUR 2.56
- LEGN N/A
- Revenue
- FOUR $3,610,700,000.00
- LEGN $796,838,000.00
- Revenue This Year
- FOUR $28.63
- LEGN $70.27
- Revenue Next Year
- FOUR $24.09
- LEGN $50.28
- P/E Ratio
- FOUR $28.81
- LEGN N/A
- Revenue Growth
- FOUR 23.86
- LEGN 74.75
- 52 Week Low
- FOUR $68.09
- LEGN $27.34
- 52 Week High
- FOUR $127.50
- LEGN $47.79
- Technical
- Relative Strength Index (RSI)
- FOUR 24.02
- LEGN 41.50
- Support Level
- FOUR $73.50
- LEGN $30.77
- Resistance Level
- FOUR $80.98
- LEGN $34.80
- Average True Range (ATR)
- FOUR 2.84
- LEGN 1.52
- MACD
- FOUR -0.42
- LEGN 0.17
- Stochastic Oscillator
- FOUR 3.33
- LEGN 30.02
About FOUR Shift4 Payments Inc.
Shift4 Payments Inc is provider of integrated payment processing and technology solutions. The company offers software providers a single integration to an end-to-end payments offering, a powerful gateway and a robust suite of technology solutions (including cloud enablement, business intelligence, analytics, and mobile) to enhance the value of their software suites and simplify payment acceptance. The company derives maximum revenue from United States.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.